Research and development of anti-Parkinson’s drugs: an analysis from the perspective of technology flows measured by patent citations

References

• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3(1):17013.
   Google Scholar
• WhettenGoldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc. 1997;45(7):844–849. PubMed PMID: WOS:A1997XH93300010.
   PubMed Web of Science ®Google Scholar
• Comin D, Mestieri M. Technology diffusion: measurement, causes, and consequences. In: Aghion P, Durlauf SN, editors. Handbook of economic growth, vols 2a and 2b. Handbooks in economics. Amsterdam: Elsevier North Holland; 2014. p. 565–622.
   Google Scholar
• Youn HJ, Strumsky D, Bettencourt LMA, et al. Invention as a combinatorial process: evidence from US patents. J R Soc Interface. 2015;12(106): PubMed PMID: WOS:000353359900044.
   Web of Science ®Google Scholar
• Yang G-C, Li G, Li C-Y, et al. Using the comprehensive patent citation network (CPC) to evaluate patent value. Scientometrics. 2015;105(3):1319–1346.
   Web of Science ®Google Scholar
• Karki MMS. Patent citation analysis: a policy analysis tool. World Pat Inf. 1997;19(4):269–272.
   Google Scholar
• Chang S-B, Lai K-K, Chang S-M. Exploring technology diffusion and classification of business methods: using the patent citation network. Technol Forecasting Soc Change. 2009;76(1):107–117.
   Web of Science ®Google Scholar
• Xu J, Kong X, Qiu L, et al. Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations. Expert Opin Ther Pat. 2014;24(7):791–800.
   PubMed Web of Science ®Google Scholar
• Érdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the US patent citation network. Scientometrics. 2012;95(1):225–242.
   Web of Science ®Google Scholar
• Xu JC, Kong XJ, Qiu L, et al. Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations. Expert Opin Ther Pat. 2014;24(7):791–800. PubMed PMID: WOS:000337912900006.
   PubMed Web of Science ®Google Scholar
• Kong X, Hu Y, Cai Z, et al. Dendritic-cell-based technology landscape: insights from patents and citation networks. Hum Vaccin Immunother. 2015;11(3):682–688. PubMed PMID: 25714961; PubMed Central PMCID: PMCPMC4514221.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kong X, Zheng J, et al. Research and development of antibiotics: insights from patents and citation network. Expert Opin Ther Pat. 2016;26(5):617–627. PubMed PMID: 26986226.
   PubMed Web of Science ®Google Scholar
• Akkari ACS, Munhoz IP, Tomioka J, et al. Inovação tecnológica na indústria farmacêutica: diferenças entre a Europa, os EUA e os países farmaemergentes. Gestão Produção. 2016;23(2):365–380.
   Google Scholar
• Liu K, Lin H-H, Pi R, et al. Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows. Expert Opin Ther Pat. 2018;28(4):341–350.
   PubMed Web of Science ®Google Scholar
• Huang C, Lin HH, Wan JB, et al. Research and development of hepatitis B drugs: an analysis based on technology flows measured by patent citations. PLoS One. 2016;11(10):e0164328. Epub 2016/10/12. PubMed PMID: 27727319; PubMed Central PMCID: PMCPMC5058496.
   PubMed Web of Science ®Google Scholar
• Kong X, Zhang Q, Lai Y, et al. Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opin Ther Pat. 2018;28(1):69–80. Epub 2017/09/12. PubMed PMID: 28891360.
   PubMed Web of Science ®Google Scholar
• Gold BG, Villafranca JE. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem. 2003;3(12):1368–1375.
   PubMed Web of Science ®Google Scholar
• Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs. 2000;9(10):2331–2342.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Epub 2014/04/24. PubMed PMID: 24756517 JAMA. 2014;31116:1670–1683.
   PubMed Web of Science ®Google Scholar
• Bocquet A, Lorent G, Fuks B, et al. Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J Pharmacol. 2001;415(2):173–180.
   PubMed Web of Science ®Google Scholar
• Taylor JB, Triggle DJ. Comprehensive medicinal chemistry II. Oxford: Elsevier; 2007.
   Google Scholar
• Alizadeh R, Mehrabi S, Hadjighassem M. Cell therapy in Parkinson’s disease. Arch Neurosci. 2013;1(2):43–50.
   Google Scholar
• Kordower JH. Gene therapy for Parkinson’s disease: still a hot topic? Epub 2014/12/09. PubMed PMID: 25482182; PubMed Central PMCID: PMCPMC4262915 Neuropsychopharmacology. 2015;401:255–256.
   PubMed Web of Science ®Google Scholar
• Surmeier DJ, Sanchez J, Guzman J, et al., inventors; Northwestern University, assignee. Treatment for dopaminergic disorders. United States patent US 9,463,186. 2016 Oct 11
   Google Scholar
• Kang UJ, inventor; Arch Development Corp, assignee. Vesicular monoamine transporter gene therapy in Parkinson’s disease. United States patent US 6,506,378. 2003 Jan 14
   Google Scholar
• Chiesi P, inventor; Chiesi Farmaceutici SpA, assignee. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof. United States patent US 4,826,875. 1989 May 2
   Google Scholar
• Edgren DE, Carpenter HA, Bhatti GK, et al., inventors; Alza Corp, assignee. Dosage form indicated for the management of abnormal posture, tremor and involuntary movement. United States patent US 5,190,763. 1993 Mar 2
   Google Scholar
• Edgren DE, Carpenter HA, Bhatti GK, et al., inventors; Alza Corp, assignee. Dosage form for treating central nervous system disorders. United States patent US 5,192,550. 1993 Mar 9
   Google Scholar
• Scott J, Carrington PJ. The SAGE handbook of social network analysis. London: SAGE publications; 2011.
   Google Scholar
• Schenk DB, Games KD, Buttini MJ, et al., inventors; Elan Pharmaceuticals LLC, assignee. Treatment and delay of onset of synucleinopathic and amyloidogenic disease. United States patent US 7,919,088. 2011 Apr 5
   Google Scholar
• Wolozin B, Ostretova-Golts N, Lebowitz MS, inventors; Panacea Pharmaceuticals Inc, assignee. Compositions for inhibiting the aggregation pathway of α-synuclein. United States patent US 6,780,971. 2004 Aug 24
   Google Scholar
• Karvonen M, Daim TU, Kässi T. Patent analysis for analysing technological convergence. Foresight. 2011;13(5):34–50.
   Google Scholar
• Dong J, Cui YH, Li S, et al. Current pharmaceutical treatments and alternative therapies of Parkinson’s disease. Curr Neuropharmacol. 2016;14(4):339–355. PubMed PMID: WOS:000374878300007.
   PubMed Web of Science ®Google Scholar
• Onofrj M, Frazzini V, Bonanni L, et al. Amantadine and antiglutamatergic drugs in the management of Parkinson’s disease. In: Espay AJ, Fernandez HH, Gálvez-Jiménez N, et al., editors. Parkinson’s disease: current and future therapeutics and clinical trials. Cambridge: Cambridge University Press; 2016. 13–22.
   Google Scholar
• Emborg ME, Shin P, Roitberg B, et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol. 2001;168(1):171–182. Epub 2001/02/15. PubMed PMID: 11170732.
   PubMed Web of Science ®Google Scholar
• Gold BG, Nutt JG. Neuroimmunophilin ligands in the treatment of Parkinson’s disease. PubMed PMID: WOS:000176154400011 Curr Opin Pharmacol. 2002;21:82–86.
   PubMed Web of Science ®Google Scholar
• Wood H. Parkinson disease: A monoclonal antibody targeting misfolded alpha-synuclein has therapeutic potential in Parkinson disease. Epub 2014/07/09. PubMed PMID: 25002110 Nat Rev Neurol. 2014;108:426.
   PubMedGoogle Scholar
• Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA. 2010;107(36):15921–15926. Epub 2010/08/28. PubMed PMID: 20798034; PubMed Central PMCID: PMCPMC2936617.
   PubMed Web of Science ®Google Scholar
• Taymans JM, Greggio E. LRRK2 kinase inhibition as a therapeutic strategy for Parkinson’s disease, where do we stand? Curr Neuropharmacol. 2016;14(3): 214–225. PubMed PMID: WOS:000373453200002.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Okuno T, Asari S, et al. Cell therapy for Parkinson’s disease. In: Bhattacharya N, Stubblefield P, editors. Human Fetal Tissue Transplantation. London: Springer London; 2013. p. 193–203.
   Google Scholar
• Hanna E, Rémuzat C, Auquier P, et al. Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy. 2017;5(1). DOI:10.1080/20016689.2017.1265293
   PubMedGoogle Scholar
• West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Epub 2017/08/03. PubMed PMID: 28764903; PubMed Central PMCID: PMCPMC5693612 Exp Neurol. 2017;298Pt B:236–245.
   PubMedGoogle Scholar
• Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89(1): 37–47. Epub 2016/08/10. PubMed PMID: 27505015; PubMed Central PMCID: PMCPMC4797835.
   PubMedGoogle Scholar
• Cacciatore I, Ciulla M, Marinelli L, et al. Advances in prodrug design for Parkinson’s disease. Expert Opin Drug Discov. 2018;13(4):295–305. Epub 2018/01/25. PubMed PMID: 29361853.
   PubMed Web of Science ®Google Scholar
• Wen MM. Advances and challenges in the dosage form design for the treatment of Parkinson’s disease. Discov Med. 2012;14(79):369–377. PubMed PMID: WOS:000315299900002.
   PubMed Web of Science ®Google Scholar
• Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82–85.
   PubMed Web of Science ®Google Scholar
• Lu CT, Zhao YZ, Wong HL, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014;9:2241–2257. Epub 2014/05/30. PubMed PMID: 24872687; PubMed Central PMCID: PMCPMC4026551.
   PubMed Web of Science ®Google Scholar
• Fox SH, New Clinical B-BI. Trials for levodopa-induced dyskinesia. In: Fox SH, Brotchie JM, editors. Levodopa-induced dyskinesia in Parkinson’s disease. London: Springer London; 2014. p. 301–333.
   Google Scholar
• Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol. 2007;7:20. Epub 2007/07/20. PubMed PMID: 17634109; PubMed Central PMCID: PMCPMC1931606.
   PubMed Web of Science ®Google Scholar
• Shin JY, Habermann B. Medication adherence in people with Parkinson disease. Epub 2016/05/26. PubMed PMID: 27224682 J Neurosci Nurs. 2016;484:185–194.
   PubMed Web of Science ®Google Scholar
• Garbayo E, Ansorena E, Blanco-Prieto MJ. Drug development in Parkinson’s disease: from emerging molecules to innovative drug delivery systems. Epub 2013/07/06. PubMed PMID: 23827471 Maturitas. 2013;763:272–278.
   PubMed Web of Science ®Google Scholar
• Andrade C. Sustained-release, extended-release, and other time-release formulations in neuropsychiatry. Epub 2015/09/04. PubMed PMID: 26335096 J Clin Psychiatry. 2015;768:e995–9.
   PubMed Web of Science ®Google Scholar
• Tayarani-Binazir KA, Jackson MJ, Rose S, et al. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord. 2010;25(3):377–384. Epub 2010/01/29. PubMed PMID: 20108359.
   PubMed Web of Science ®Google Scholar
• Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. PubMed PMID: WOS:000339862100007 Expert Opin Drug Saf. 2014;138:1055–1069.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Pan W, Hu YJ, et al. Multi-target drugs: the trend of drug research and development. PLoS One. 2012;7(6):e40262. Epub 2012/07/07. PubMed PMID: 22768266; PubMed Central PMCID: PMCPMC3386979.
   PubMed Web of Science ®Google Scholar
• Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855–866.
   PubMed Web of Science ®Google Scholar